{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:03:15Z","timestamp":1793822595269,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017599","name":"Science and Technology Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2021C03010"],"award-info":[{"award-number":["2021C03010"]}],"id":[{"id":"10.13039\/501100017599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020774","name":"Major Projects of Special Development Funds in Zhangjiang National Independent Innovation Demonstration Zone, Shanghai","doi-asserted-by":"publisher","award":["H25"],"award-info":[{"award-number":["H25"]}],"id":[{"id":"10.13039\/501100020774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0507001"],"award-info":[{"award-number":["2018YFA0507001"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFA0802802"],"award-info":[{"award-number":["2019YFA0802802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772622"],"award-info":[{"award-number":["81772622"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870153"],"award-info":[{"award-number":["81870153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130003"],"award-info":[{"award-number":["82130003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270234"],"award-info":[{"award-number":["82270234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.eclinm.2023.102010","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:05:52Z","timestamp":1684393552000},"page":"102010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study"],"prefix":"10.1016","volume":"60","author":[{"given":"Yongxian","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2023.102010_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102010_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"6382","key":"10.1016\/j.eclinm.2023.102010_bib3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102010_bib4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102010_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.eclinm.2023.102010_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102010_bib7","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/acg2.86","article-title":"Toward \u201coff-the-shelf\u201d allogeneic CAR T cells","volume":"3","author":"Aftab","year":"2020","journal-title":"Adv Cell Gene Ther"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102010_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.eclinm.2023.102010_bib9","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102010_bib10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102010_bib11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102010_bib12","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102010_bib13","doi-asserted-by":"crossref","first-page":"E1337","DOI":"10.3390\/cells9061337","article-title":"Transposon-based CAR T cells in acute leukemias: where are we going?","volume":"9","author":"Magnani","year":"2020","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102010_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102010_bib15","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"16_Supplement","key":"10.1016\/j.eclinm.2023.102010_bib16","doi-asserted-by":"crossref","first-page":"CT052","DOI":"10.1158\/1538-7445.AM2020-CT052","article-title":"Abstract CT052: clinical safety and efficacy study of TruUCAR\u2122 GC027: the first-in-human, universal CAR-T therapy for adult relapsed\/refractory T-cell acute\u00a0lymphoblastic leukemia (r\/r T-ALL)","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.eclinm.2023.102010_bib17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"21","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102010_bib18","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"7643","key":"10.1016\/j.eclinm.2023.102010_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102010_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","article-title":"One-step generation of modular CAR-T cells with AAV-Cpf1","volume":"16","author":"Dai","year":"2019","journal-title":"Nat Methods"},{"issue":"7926","key":"10.1016\/j.eclinm.2023.102010_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102010_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102010_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"10.1016\/j.eclinm.2023.102010_bib24","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.eclinm.2023.102010_bib25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102010_bib26","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102010_bib27","series-title":"Acute lymphoblastic leukemia guideline detail","year":"2023"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102010_bib28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102010_bib29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving Rituximab","volume":"161","author":"Park","year":"2022","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102010_bib30","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102010_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"10.1016\/j.eclinm.2023.102010_bib32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102010_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102010_bib34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","article-title":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.eclinm.2023.102010_bib35","first-page":"578","article-title":"Long-term follow-up ZUMA-1: a pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-hodgkin lymphoma (NHL)","volume":"130","author":"Neelapu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102010_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102010_bib37","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102010_bib38","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102010_bib39","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102010_bib40","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A\u00a0phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102010_bib41","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102010_bib42","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"57","key":"10.1016\/j.eclinm.2023.102010_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A\u00a0cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102010_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102010_bib45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102010_bib46","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver injury increases the incidence of HCC following AAV gene therapy in mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102010_bib47","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2006-08-044156","article-title":"Retroviral vector insertion sites associated with dominant hematopoietic clones mark \u201cstemness\u201d pathways","volume":"109","author":"Kustikova","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102010_bib48","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ymthe.2005.07.358","article-title":"Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice","volume":"12","author":"Themis","year":"2005","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102010_bib49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102010_bib50","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran","year":"2020","journal-title":"Int J Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023001876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023001876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:18:16Z","timestamp":1762899496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023001876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":50,"alternative-id":["S2589537023001876"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102010","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102010"}}